Table 3: Overall survival and values of Atezolizumab and Pembrolizomab.
Drug and setting | OS gains in days/Grade (OS/gr) & HR | $C/LYG | RV |
---|---|---|---|
Atezo vs. Docetaxel (Doc), irrespective of PD-L1, vs. Docetaxel (phase II, Poplar) [8] | 87/C HR 0.73 P = 0.040 |
$618,244 | 0.16 |
Atezo, squamous and non-squamous, regardless of PD-L1 vs. Doc (OAK) [9] | 128/B HR 0.74 P = 0.0004 |
$420,213 | 0.24 |
Atezo, low or undetectable PD-L1 vs. Doc, Phase III OAK [10] | 111/B HR 0.75 | $484,570 | 0.21 |
Atezo, PD-L1 > 1.0% or tumor-infiltrating immune cells vs. Doc [10] | 162/A HR 0.74 P = 0.0102 |
$332,020 | 0.30 |
Pembro PD-L1 > 1.0% positive vs. Doc Keynote-010 [7] Subset analysis | 57/C HR 0.71 P = 0.0008 |
$659,059 | 0.15 |
Pembro 10 mg/Kg, PD-L1 1.0% positive, Keynote-010 | 126/A HR 0.61 |
$1,490,729 | 0.07 |
Pembro 2.0 mg/Kg, > 50% positive Keynote-010 | 201/A HR 0.54 |
$186,897 | 0.53 |